# APRE (Aprea Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Aprea Therapeutics, Inc. reported $38.81M in total assets and a net loss of $14.14M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/APRE
- Markdown: https://convexityos.com/fundamentals/APRE.md
- SEC CIK: 0001781983
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:09 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001781983&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$15.28M | Operating profit |
| Net Income | FY 2025 | -$14.14M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.26 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $37.85M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $7.04M | $9.36M | $7.63M | $16.40M | $23.90M | $37.88M | $20.95M | $14.19M | $13.39M |
| Total Operating Expenses | $13.52M | $15.82M | $16.06M | $113.4M | $37.45M | $52.81M | $29.54M | $16.49M | $15.85M |
| **Operating Income** | -$13.23M | -$14.32M | -$15.47M | -$113.4M | -$37.45M | -- | -- | -- | -- |
| **EBITDA** | -$13.21M | -$14.30M | -$15.46M | -$113.4M | -$37.43M | -- | -- | -- | -- |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$12.60M | -$12.96M | -$14.29M | -$112.7M | -$37.13M | -$53.48M | -$28.06M | -$15.53M | -$15.19M |
| Basic EPS | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$93.40 | -$269.00 | -$263.40 |
| **Diluted EPS** | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$93.40 | -$269.00 | -$263.40 |
| Basic Shares Outstanding | 6.5M | 5.5M | 3.6M | 1.7M | 1.1M | 1.1M | 300.1K | 57.7K | 57.7K |
| Diluted Shares Outstanding | 6.5M | 5.5M | 3.6M | 1.7M | 1.1M | 1.1M | 300.1K | 57.7K | 57.7K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $3.34M | $2.46M | $1.61M | $1.01M | $1.64M | $1.91M | $2.48M | $2.36M |
| Total Operating Expenses | $5.17M | $4.03M | $3.43M | $2.65M | $3.12M | $3.51M | $4.25M | $3.43M |
| **Operating Income** | -$5.17M | -$4.03M | -$3.43M | -$2.64M | -$3.12M | -$3.39M | -$4.09M | -$3.23M |
| **EBITDA** | -$5.17M | -$4.03M | -$3.42M | -$2.64M | -$3.11M | -$3.38M | -$4.08M | -$3.22M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$4.81M | -$3.59M | -$3.29M | -$2.46M | -$2.97M | -$3.24M | -$3.93M | -$2.89M |
| Basic EPS | -$0.09 | -$0.07 | -$0.22 | -- | -$0.47 | -$0.53 | -$0.66 | -- |
| **Diluted EPS** | -$0.09 | -$0.07 | -$0.22 | -- | -$0.47 | -$0.53 | -$0.66 | -- |
| Basic Shares Outstanding | 53.7M | 53.5M | 14.7M | -- | 6.4M | 6.1M | 6.0M | -- |
| Diluted Shares Outstanding | 53.7M | 53.5M | 14.7M | -- | 6.4M | 6.1M | 6.0M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $14.60M | $22.85M | $21.61M | $28.79M | $53.08M | $89.02M | $130.1M | $65.68M |
| **Cash & Short-Term Investments** | $14.60M | $22.85M | $21.61M | $28.79M | $53.08M | $89.02M | $130.1M | $65.68M |
| **Total Current Assets** | $15.56M | $23.58M | $22.52M | $30.15M | $56.58M | $92.42M | $133.0M | $66.00M |
| Property, Plant & Equipment, Net | $60K | $82K | $88K | $2.3K | $24K | $39K | $42K | $24K |
| Other Non-Current Assets | $271K | $282K | -- | -- | $29K | $29K | $107 | $111 |
| **Total Non-Current Assets** | $372K | $403K | $129K | $2.3K | $239K | $389K | $563K | $25K |
| **Total Assets** | $15.93M | $23.98M | $22.65M | $30.16M | $56.82M | $92.81M | $133.6M | $66.02M |
| Accounts Payable | $714K | $1.35M | $1.67M | $843K | $1.77M | $4.50M | $2.18M | $1.74M |
| Deferred Revenue (Current) | -- | -- | $529K | -- | -- | -- | -- | -- |
| **Total Current Liabilities** | $2.76M | $3.36M | $4.39M | $3.20M | $7.32M | $15.33M | $9.06M | $4.87M |
| **Total Non-Current Liabilities** | $727K | $1.31M | $1.31M | $0 | $0 | $79K | $303K | $0 |
| **Total Liabilities** | $3.49M | $4.67M | $5.70M | $3.20M | $7.32M | $15.41M | $9.36M | $4.87M |
| **Total Debt (incl. Leases)** | -- | -- | -- | -- | $190K | $335K | $545K | -- |
| Common Stock | $8.2K | $5.5K | $3.7K | $2.7K | $1.1K | $21K | $21K | $127K |
| Retained Earnings | -$333.6M | -$321.0M | -$308.1M | -$293.8M | -$181.1M | -$144.0M | -$90.53M | -$62.47M |
| Accumulated Other Comp. Income | -$10.63M | -$10.63M | -$10.61M | -$10.62M | -$10.36M | -$10.04M | -$11.53M | -$8.76M |
| **Total Stockholders' Equity** | $12.44M | $19.31M | $16.95M | $25.64M | $49.51M | $77.40M | $124.2M | -$51.44M |
| Total Equity | $12.44M | $19.31M | $16.95M | $25.64M | $49.51M | $77.40M | $124.2M | -$51.44M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $37.85M | $41.23M | $46.47M | $14.60M | $13.72M | $16.53M | $19.28M | $22.85M |
| **Cash & Short-Term Investments** | $37.85M | $41.23M | $46.47M | $14.60M | $13.72M | $16.53M | $19.28M | $22.85M |
| **Total Current Assets** | $38.44M | $41.91M | $47.25M | $15.56M | $13.94M | $16.93M | $19.83M | $23.58M |
| Property, Plant & Equipment, Net | $62K | $64K | $54K | $60K | $65K | $71K | $76K | $82K |
| Other Non-Current Assets | $271K | $271K | $271K | $271K | $271K | $271K | $271K | $282K |
| **Total Non-Current Assets** | $375K | $377K | $367K | $372K | $377K | $382K | $388K | $403K |
| **Total Assets** | $38.81M | $42.29M | $47.61M | $15.93M | $14.32M | $17.31M | $20.22M | $23.98M |
| Accounts Payable | $1.26M | $935K | $2.94M | $714K | $641K | $1.20M | $1.28M | $1.35M |
| **Total Current Liabilities** | $3.97M | $3.09M | $5.30M | $2.76M | $2.68M | $3.17M | $3.36M | $3.36M |
| **Total Non-Current Liabilities** | $727K | $727K | $727K | $727K | $727K | $727K | $1.31M | $1.31M |
| **Total Liabilities** | $4.70M | $3.82M | $6.02M | $3.49M | $3.41M | $3.90M | $4.67M | $4.67M |
| Common Stock | $14K | $12K | $12K | $8.2K | $6.0K | $5.8K | $5.5K | $5.5K |
| Retained Earnings | -$345.3M | -$340.5M | -$336.9M | -$333.6M | -$331.2M | -$328.2M | -$325.0M | -$321.0M |
| Accumulated Other Comp. Income | -$10.61M | -$10.62M | -$10.63M | -$10.63M | -$10.63M | -$10.63M | -$10.63M | -$10.63M |
| **Total Stockholders' Equity** | $34.11M | $38.47M | $41.59M | $12.44M | $10.91M | $13.41M | $15.55M | $19.31M |
| Total Equity | $34.11M | $38.47M | $41.59M | $12.44M | $10.91M | $13.41M | $15.55M | $19.31M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$12.60M | -$12.96M | -$14.29M | -$112.7M | -$37.13M | -$53.48M | -$28.06M | -$15.53M | -$15.19M |
| Depreciation & Amortization | $22K | $22K | $7.1K | $4.4K | $13K | $29K | $11K | $8.3K | $7.9K |
| Stock-Based Compensation | -- | -- | -- | -- | -- | $4.98M | $1.35M | $330K | $395K |
| Change in Payables | -$647K | -$314K | $827K | -$859K | -$2.73M | $2.33M | $438K | $214K | $327K |
| **Operating Cash Flow** | -$12.89M | -$13.56M | -$12.18M | -$25.01M | -$37.69M | -$41.80M | -$26.71M | -$15.25M | -$14.00M |
| Capital Expenditure | -- | -$15K | -$93K | -- | -- | -$26K | -$31K | -$3.7K | -- |
| **Free Cash Flow** | -- | -$13.57M | -$12.27M | -- | -- | -$41.83M | -$26.74M | -$15.25M | -- |
| **Investing Cash Flow** | -- | -$15K | -$93K | -- | -- | -$26K | -$31K | -$3.7K | -- |
| Common Stock Issued | $5.05M | $16.14M | $5.79M | $683K | $1.54M | -- | -- | -- | -- |
| **Financing Cash Flow** | $4.64M | $14.82M | $5.14M | $683K | $1.75M | $151K | $92.58M | $56.37M | $23.34M |
| **Net Change in Cash** | -$8.25M | $1.25M | -$7.13M | -$24.33M | -$35.94M | -$41.68M | $65.84M | $41.11M | $9.34M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$4.81M | -$3.59M | -$3.29M | -$2.46M | -$2.97M | -$3.24M | -$3.93M | -$2.89M |
| Depreciation & Amortization | $5.9K | $5.7K | $5.4K | $5.4K | $5.4K | $5.4K | $5.4K | $5.4K |
| Stock-Based Compensation | $100K | $100K | -- | -- | $100K | $100K | $100K | -- |
| Change in Payables | $323K | $190K | $33K | $69K | -$554K | -$90K | -$72K | $202K |
| **Operating Cash Flow** | -$3.73M | -$3.28M | -$2.76M | -$2.96M | -$3.17M | -$3.13M | -$3.63M | -$3.51M |
| Capital Expenditure | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Free Cash Flow** | -- | -- | -- | -- | -- | -- | -- | -$3.51M |
| **Investing Cash Flow** | -- | -- | -- | -- | -- | -- | -- | $0 |
| Common Stock Issued | $0 | $500K | $35.10M | $4.21M | $375K | $400K | $59K | $141K |
| **Financing Cash Flow** | $342K | -$1.94M | $34.62M | $3.84M | $358K | $385K | $56K | $134K |
| **Net Change in Cash** | -- | -- | $31.87M | $880K | -$2.81M | -$2.75M | -$3.58M | -$3.38M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -101.3% | -67.1% | -84.3% | -439.3% | -75.0% | -69.1% | -22.6% | -- | -- |
| Return on Assets (ROA) | -79.1% | -54.0% | -63.1% | -373.6% | -65.3% | -57.6% | -21.0% | -23.5% | -- |
| Current Ratio | 5.63x | 7.01x | 5.14x | 9.42x | 7.73x | 6.03x | 14.68x | 13.56x | -- |
| Quick Ratio | 5.28x | 6.80x | 4.93x | 8.99x | 7.25x | 5.81x | 14.36x | 13.49x | -- |
| Debt to Equity | -- | -- | -- | -- | 0.00x | 0.00x | 0.00x | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -41.5% | -32.0% | -28.7% | -101.3% | -119.5% | -103.2% | -90.6% | -67.1% |
| Return on Assets (ROA) | -36.4% | -29.1% | -25.1% | -79.1% | -91.0% | -80.0% | -69.6% | -54.0% |
| Current Ratio | 9.67x | 13.55x | 8.92x | 5.63x | 5.20x | 5.34x | 5.90x | 7.01x |
| Quick Ratio | 9.52x | 13.33x | 8.77x | 5.28x | 5.12x | 5.22x | 5.73x | 6.80x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
